Health Care

Jiangsu Hengrui Pharma’s robust drug pipeline and rising policy support position it to capture China’s expanding anti‑cancer market, boosting investor confidence.

Harbin Pharmaceutical’s three‑board surge shows rising investor confidence in China’s pharma sector—yet highlights risks of high valuation and thin margins.

Quantum Cyber NV’s stable €8 share price and negative P/E highlight its biotech focus on rapid, molecular‑genetic diagnostics that aim to transform global patient care.

Unicycive Therapeutics advances novel hyperphosphatemia treatments for CKD and AKI, aiming to curb complications and attract investors with a promising pipeline.

Tilray Brands Inc. gears up for July 28 earnings, weighing cannabis volatility, a BrewDog pub event, and a downgraded analyst outlook.

Boston Scientific’s stock rebounds to $44.65 amid market volatility, showcasing its robust portfolio of minimally invasive devices and promising growth prospects for investors.

SPRO: Spero Therapeutics secures a $1.1B licensing deal for anti‑CD40L antibody IBI355 and a $105M royalty financing, boosting its IgG4‑RD and Sjögren’s disease pipeline.

Explore how Celyad Oncology’s cutting‑edge CAR‑T therapy is reshaping cancer treatment worldwide, boosting hope for aggressive cancers with limited options.

Discover how AstraZeneca Pharma India’s exclusive Zegfrovy license and new EGFR deal boost its oncology pipeline, unlock $600M upfront, and reshape cancer treatment in India.

Shanghai Fosun Pharmaceutical’s new drug clinical‑trial approval marks a breakthrough for its R&D pipeline and could boost investor confidence and market position.